文献速递乳腺癌

曲妥珠单抗美坦新对比卡培他滨加拉帕替尼治疗经治HER2阳性晚期乳腺癌患者(EMILIA):一项随机、开放标签、3期试验最终总生存结果的描述性分析

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-05-16

EMILIA研究为随机、国际、开放标签3期试验,入组991例经曲妥珠单抗和紫杉烷治疗的HER2阳性不可切除局部晚期或转移性乳腺癌患者,随机接受曲妥珠单抗美坦新或卡培他滨加拉帕替尼。最终描述性分析显示,曲妥珠单抗美坦新组中位总生存29.9个月,对照组25.9个月(HR 0.75,95%CI 0.64-0.88)。

要点

  • 曲妥珠单抗美坦新组中位总生存29.9个月,对照组25.9个月,HR 0.75(95%CI 0.64-0.88)。
  • 曲妥珠单抗美坦新组3级及以上不良事件233/490(48%),对照组291/488(60%)。
  • 对照组136/496(27%)患者交叉接受曲妥珠单抗美坦新治疗。

核心结论

  • EMILIA试验最终总生存描述性分析显示,曲妥珠单抗美坦新改善了经治HER2阳性转移性乳腺癌患者的总生存,即使存在交叉治疗。
  • 安全性特征与既往分析相似,重申曲妥珠单抗美坦新是该患者群体中有效且可耐受的治疗。

研究设计与样本

  • EMILIA为随机、国际、开放标签、3期研究,入组年龄≥18岁的HER2阳性不可切除局部晚期或转移性乳腺癌患者,既往接受过曲妥珠单抗和紫杉烷治疗。
  • 患者按1:1随机分配至曲妥珠单抗美坦新(3.6 mg/kg静脉给药,每3周一次)或对照组(卡培他滨1000 mg/m2口服每日两次,每21天周期第1-14天;加拉帕替尼1250 mg口服每日一次,第1-21天)。
  • 随机分层因素包括世界区域(美国 vs 西欧 vs 其他)、既往针对不可切除局部晚期或转移性疾病的化疗方案数(0或1 vs >1)和疾病受累(内脏 vs 非内脏)。
  • 共同主要疗效终点为无进展生存(独立评审委员会评估)和总生存;疗效在意向治疗人群中分析,安全性在至少接受一剂研究治疗的患者中按实际治疗分析。
  • 2009年2月23日至2011年10月13日,共入组991例合格患者,随机分配至曲妥珠单抗美坦新组(n=495)或卡培他滨加拉帕替尼对照组(n=496)。

主要发现

  • 最终描述性分析中,曲妥珠单抗美坦新组中位总生存为29.9个月(95%CI 26.3-34.1),对照组为25.9个月(95%CI 22.7-28.3),HR 0.75(95%CI 0.64-0.88)。
  • 第二次中期总生存分析后,对照组496例患者中136例(27%)交叉接受曲妥珠单抗美坦新治疗(中位随访时间24.1个月,IQR 19.5-26.1)。
  • 最初随机分配至曲妥珠单抗美坦新组的495例患者中,254例(51%)在研究药物停药后接受卡培他滨,241例(49%)接受拉帕替尼(单独或联合)。
  • 安全性人群中,曲妥珠单抗美坦新组490例患者中233例(48%)发生3级及以上不良事件,对照组488例患者中291例(60%)发生。
  • 对照组最常见的3级及以上不良事件为腹泻(488例中103例,21%)、手掌-足底红斑感觉异常综合征(87例,18%)和呕吐(24例,5%);曲妥珠单抗美坦新组为血小板减少(490例中70例,14%)、天冬氨酸氨基转移酶升高(22例,5%)和贫血(19例,4%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The antibody-drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progression-free survival and interim overall survival data from the phase 3 EMILIA study. In this report, we present a descriptive analysis of the final overall survival data from that trial. METHODS: EMILIA was a randomised, international, open-label, phase 3 study of men and women aged 18 years or older with HER2-positive unresectable, locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. Enrolled patients were randomly assigned (1:1) via a hierarchical, dynamic randomisation scheme and an interactive voice response system to trastuzumab emtansine (3·6 mg/kg intravenously every 3 weeks) or control (capecitabine 1000 mg/m2 self-administered orally twice daily on days 1-14 on each 21-day cycle, plus lapatinib 1250 mg orally once daily on days 1-21). Randomisation was stratified by world region (USA vs western Europe vs or other), number of previous chemotherapy regimens for unresectable, locally advanced, or metastatic disease (0 or 1 vs >1), and disease involvement (visceral vs non-visceral). The coprimary efficacy endpoints were progression-free survival (per independent review committee assessment) and overall survival. Efficacy was analysed in the intention-to-treat population; safety was analysed in all patients who received at least one dose of study treatment, with patients analysed according to the treatment actually received. On May 30, 2012, the study protocol was amended to allow crossover from control to trastuzumab emtansine after the second interim overall survival analysis crossed the prespecified overall survival efficacy boundary. This study is registered with ClinicalTrials.gov, number NCT00829166. FINDINGS: Between Feb 23, 2009, and Oct 13, 2011, 991 eligible patients were enrolled and randomly assigned to either trastuzumab emtansine (n=495) or capecitabine and lapatinib (control; n=496). In this final descriptive analysis, median overall survival was longer with trastuzumab emtansine than with control (29·9 months [95% CI 26·3-34·1] vs 25·9 months [95% CI 22·7-28·3]; hazard ratio 0·75 [95% CI 0·64-0·88]). 136 (27%) of 496 patients crossed over from control to trastuzumab emtansine after the second interim overall survival analysis (median follow-up duration 24·1 months [IQR 19·5-26·1]). Of those patients originally randomly assigned to trastuzumab emtansine, 254 (51%) of 495 received capecitabine and 241 [49%] of 495 received lapatinib (separately or in combination) after study drug discontinuation. In the safety population (488 patients treated with capecitabine plus lapatinib, 490 patients treated with trastuzumab emtansine), fewer grade 3 or worse adverse events occurred with trastuzumab emtansine (233 [48%] of 490) than with capecitabine plus lapatinib control treatment (291 [60%] of 488). In the control group, the most frequently reported grade 3 or worse adverse events were diarrhoea (103 [21%] of 488 patients) followed by palmar-plantar erythrodysaesthesia syndrome (87 [18%]), and vomiting (24 [5%]). The safety profile of trastuzumab emtansine was similar to that reported previously; the most frequently reported grade 3 or worse adverse events in the trastuzumab emtansine group were thrombocytopenia (70 [14%] of 490), increased aspartate aminotransferase levels (22 [5%]), and anaemia (19 [4%]). Nine patients died from adverse events; five of these deaths were judged to be related to treatment (two in the control group [coronary artery disease and multiorgan failure] and three in the trastuzumab emtansine group [metabolic encephalopathy, neutropenic sepsis, and acute myeloid leukaemia]). INTERPRETATION: This descriptive analysis of final overall survival in the EMILIA trial shows that trastuzumab emtansine improved overall survival in patients with previously treated HER2-positive metastatic breast cancer even in the presence of crossover treatment. The safety profile was similar to that reported in previous analyses, reaffirming trastuzumab emtansine as an efficacious and tolerable treatment in this patient population. FUNDING: F Hoffmann-La Roche/Genentech.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017. PMID: 28526536. doi:10.1016/S1470-2045(17)30312-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。